We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Partners Seek to Develop Rare Monoclonal Antibodies for Therapeutic Use

By LabMedica International staff writers
Posted on 15 Feb 2016
Print article
A recently publicized collaborative research agreement is set to boost the use of a high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies for therapeutic use.

Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) and AbCellera (Vancouver, BC, Canada) have agreed to collaborate in a research program that will expand the use of AbCellar's proprietary antibody discovery system.

The AbCellera system is based on isolating single antibody-secreting cells in nanoliter-volume chambers, which allows secreted antibodies to be detected within hours with a variety of bead-based and cell-based assay formats. Combining ultra-high-throughput screening with enhanced sensitivity and flexibility means the microfluidic platform can deliver high-quality monoclonal antibody therapeutic candidates with exceptional speed. Small volume chambers ensure that millions of cells can be screened at the same time based on binding properties and antibody function, focusing downstream analysis on potentially high value antibodies. State-of-the art automation during cell processing and recovery, combined with deep technical expertise guarantees the rapid and effective identification of rare antibodies with the desired therapeutic properties.

Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and will be eligible to receive undisclosed downstream milestone payments associated with the development and approval of therapeutic antibodies.

“We are pleased to work with AbCellera utilizing this company’s novel biologics technology,” said Dr. Michael Hayden, president of global R&D and CSO at Teva Pharmaceutical Industries Ltd. “This agreement will be complementary to our existing antibody discovery process with the potential to strengthen Teva’s capabilities in novel biologics discovery.”

“These are tough problems that need new technologies to move them forward. Our platform brings important advantages to enable the discovery of rare antibodies with defined specificity and functional activity against difficult membrane protein targets,” said Dr. Carl Hansen, president and CEO of AbCellera. “We look forward to a close collaboration with the team of scientists at Teva, and are excited at the chance to help advance this important program.”

Related Links:

Teva Pharmaceutical Industries Ltd.
AbCellera


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.